Role of human umbilical cord mesenchymal stem cells in diabetic kidney disease

Abstract

One of the most prevalent long-term effects of diabetes is diabetic kidney disease (DKD), which is linked to problems with the metabolism of amino acids, fats, and carbohydrates. The fundamental pathogenic mechanisms of DKD cannot be adequately treated by current clinical medicines; they can only slow the illness’s progression to end-stage renal disease. We will concentrate on integrating human umbilical cord mesenchymal stem cell (hUC-MSC)-related mechanisms and potential applications into the therapy of DKD, as this work shows that hUC-MSCs can be used to treat metabolic liver obesity associated with diabetes. Future studies on the connection between hUC-MSCs and related illnesses ought to be promoted.

Keywords: Human umbilical cord mesenchymal stem cells; Diabetes; Diabetic kidney disease; Metabolic dysregulation; Metabolic dysfunction-associated steatotic liver disease; Diabetic complications

Core Tip: This letter to the editor focuses on investigating how human umbilical cord mesenchymal stem cells (hUC-MSCs) contribute to diabetic kidney damage. At the same time, explore the similarities and differences of hUC-MSCs in treating metabolic dysfunction-associated steatotic liver disease and diabetic kidney disease. There are benefits of using hUC-MSCs to treat metabolic disorders. Future studies on the relationship between hUC-MSCs and the management of metabolic disorders ought to be promoted.